Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 7/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 8/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773452 | 0.82 | TOP2A (0.44) | F10IDO1CYP2C9KCNH2CYP3A4 | |
| SCHEMBL712171 | 0.79 | EPHX2 (0.53) | IDO1CYP3A4EPHX2 | |
| SCHEMBL709606 | 0.78 | EPHX2 (0.52) | IDO1CYP3A4EPHX2 | |
| SCHEMBL712199 | 0.78 | SSTR4 (0.40) | SSTR4 | |
| SCHEMBL708326 | 0.77 | TAS1R3 (0.50) | CACNA1HIDO1CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15967240 | 0.77 | KCNH2 (0.47) | CACNA1HIDO1CYP2C9KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL711109 | 0.76 | TAS1R3 (0.49) | CACNA1HIDO1CYP2C9KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL709864 | 0.76 | KCNH2 (0.46) | CACNA1HIDO1CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15967356 | 0.73 | KCNH2 (0.43) | CACNA1HF10IDO1CYP2C9KCNH2 | |
| SCHEMBL5506769 | 0.70 | HPGD (0.54) | KCNH2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | SSTR4 3268/4885CACNA1H 797/4885F10 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.